Uzbekistan plans Biome center for cell technologies and genomics
Uzbekistan is moving ahead with a Biome center dedicated to cell technologies, genomics, and biobanking, aiming to strengthen its position in advanced bioscience research.
Cell Therapy & Immunotherapy Products 4 articles
Cell Therapy & Immunotherapy Products encompasses named cellular medicines and broader cell-based therapeutic modalities in which living immune or stem cells provide the intervention. It includes CAR T-cell products, tumor-infiltrating lymphocytes, antigen-presenting cell therapies, stem-cell transplantation and related adoptive cell approaches. The category distinguishes engineered from non-engineered cells, autologous from allogeneic sources, and specific products from the wider immunotherapy or transplantation concepts that underpin them.
Bristol Myers Squibb's arlo-cel meets phase II goal in relapsed multiple myeloma
Bristol Myers Squibb reports that its phase II QUINTESSENTIAL trial of arlocabtagene autoleucel met the main goal in adults with relapsed and refractory multiple myeloma.
CAR-T therapy brings remission for Scottish myeloma patient after standard treatments fail
Adam Nicolson became the first person in Scotland to receive CAR-T cell therapy for myeloma after exhausting all other options. Now in remission, his case is driving new research into the therapy’s potential for autoimmune diseases.
Arovella Therapeutics gets FDA clearance to start first human trial of ALA-101 cell therapy
Arovella Therapeutics has received FDA clearance to begin Phase 1 clinical testing of its allogeneic cell therapy ALA-101 targeting CD19-positive blood cancers.